Health Trials

Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

Participants needed: 156
Trial details
Phase: Phase 1, Phase 2Age: 18-89Biological sex: AllType: InterventionalSponsor: Eikon TherapeuticsUpdated: Jun 15, 2026Locations: 57
Eligibility criteria

Breast cancer; must have received at least one prior chemotherapy in neoadjuvant... [+10]

Any investigational or approved anti-cancer therapies administered within 28 day... [+6]

Read more
Status: Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Participants needed: 750
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Eikon TherapeuticsUpdated: May 20, 2026Locations: 3
Eligibility criteria

Participant must be ≥ 18 years old at the time of signing the informed consent. [+7]

has small cell elements present histologically and/or the tumors are not predomi... [+5]

Read more
Status: Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

Participants needed: 740
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Eikon TherapeuticsUpdated: May 8, 2026Locations: 107
Eligibility criteria

Be ≥ 18 years of age on the day of signing of informed consent. [+11]

Has melanoma of ocular origin. [+20]

Read more
Status: Recruiting

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Participants needed: 160
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Eikon TherapeuticsUpdated: Apr 8, 2026Locations: 10
Eligibility criteria

is ≥ 18 years of age at the time of signing the informed consent. [+6]

has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer the... [+10]

Read more
Status: Recruiting

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2

Participants needed: 130
Trial details
Phase: Phase 1, Phase 2Age: 18-89Biological sex: AllType: InterventionalSponsor: Eikon TherapeuticsUpdated: Aug 19, 2025Locations: 10
Eligibility criteria

Age ≥ 18 years at the time of informed consent [+9]

Any investigational or approved anti-cancer therapies administered within 28 day... [+10]

Read more